HV will act as an instrument of strategic growth in broadening Hikma’s offerings; it will allow Hikma to tap into opportunities in the growing digital health space.HV will invest in companies where Hikma's expertise can accelerate revenue growth and enhance value creation by providing ventures with access to the resources of a multinational pharmaceutical company.We will invest in companies at all stages of development, including start-ups, spinouts, and consortia investments.Our initial investment size is up to $5 million per round. HV will look at global opportunities but with a focus on the US and the Middle East & Africa (MEA). We seek to actively partner with the management teams of portfolio companies to realize the potential of their products and technologies.